Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications

BACKGROUND: Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium. LXB was shown to improve cataplexy and excessive daytime sleepiness in people with narcolepsy in a placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Dauvilliers, Yves, Šonka, Karel, Bogan, Richard K., Partinen, Markku, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Skowronski, Roman, Chen, Abby, Black, Jed, Skobieranda, Franck, Thorpy, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213292/
https://www.ncbi.nlm.nih.gov/pubmed/35635687
http://dx.doi.org/10.1007/s40263-022-00926-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213292/
https://www.ncbi.nlm.nih.gov/pubmed/35635687
http://dx.doi.org/10.1007/s40263-022-00926-0

Ejemplares similares